查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026907

2034年治療診斷學市場預測－按疾病類型、技術、最終用戶和地區分類的全球分析

Theranostics Market Forecasts to 2034 - Global Analysis By Disease Type (Neurological Disorder, Immunological Disorder, Cardiovascular Disease, Oncology and Other Disease Types), Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球治療診斷學市場規模將達到 9 億美元，並在預測期內以 11.8% 的複合年成長率成長，到 2034 年將達到 23 億美元。

這個被稱為「診療整合」 （治療診斷學）的新興醫學領域，整合了治療方法和診斷方法，並將它們結合成一個綜合性的流程。 「治療診斷學」一詞由「治療」（therapy）和「診斷」（diagnostics）組合而成，強調了整合病患照護這兩個面向的重要性。它旨在根據每位患者的獨特特徵和疾病情況，提供精準的個人化治療方案。治療診斷學運用了分子影像、基因檢測、生物標記分析和分子譜分析等先進的診斷技術。

診斷技術的進步

分子影像、次世代定序(NGS) 以及磁振造影等先進診斷方法提高了疾病診斷的準確性和靈敏度。這種準確性使得識別與疾病相關的特定生物標記、基因突變或分子標靶成為可能，這對於治療診斷學至關重要，因為它可以為每位患者開發個人化藥物。此外，治療診斷學中的早期檢測能夠實現快速介入和製定個人化治療方案，從而透過提供更有效、更具針對性的療法來改善患者的預後。

缺乏關於治療診斷學檢測的明確規定

缺乏清晰明確的法規，治療診斷學檢測的核准程序、檢驗規範和品質標準都可能不清楚。這種不確定性會阻礙新診斷方法的開發和應用，並延緩突破性治療診斷學產品的上市。不清晰的法規結構和國際要求的不一致也會延緩治療診斷學檢測的上市。企業可能難以應對複雜的監管程序，導致核准等待時間延長，阻礙市場成長。

擴大研發投入

對研發的投資支持著尖端診斷設備和技術的開發。這些進步提高了診斷測試的敏感度、特異性和準確性，從而能夠更精確地識別疾病生物標記、基因變異和分子標靶。治療診斷學高度依賴診斷技術的進步來制定個人化的治療方案。市場驅動的研發成果促進了治療診斷學產品和服務的推廣和商業化，為患者和醫療專業人員提供更個人化和高效的治療選擇。

監管挑戰

嚴格的監管要求、複雜的核准程序和漫長的核准流程可能會延遲新型治療診斷學檢測和產品的上市。此類延遲可能導致患者難以按計劃獲得個人化護理和最尖端科技。不同地區的核准程序和監管要求差異可能導致市場碎片化。不一致的監管要求可能造成診療治療診斷學檢測在不同地區的可及性差異，進而導致其可用性和應用率的差異。

新冠疫情的感染疾病

此次疫情凸顯了快速且準確診斷檢測的重要性。分子診斷技術，例如聚合酶鍊式反應（PCR）和核酸擴增檢測，被廣泛用於識別SARS-CoV-2病毒。對分子診斷的重視也凸顯了類似技術在治療其他疾病（包括那些可應用於治療診斷學）的重要性。遠端醫療和遠距監測技術日益普及，以最大限度地減少面對面接觸並維持醫療服務的連續性。這種轉變可能會影響治療診斷學策略（包括遠端監測和診斷）的實施方式。

在預測期內，神經系統疾病細分市場預計將是規模最大的。

神經系統疾病領域預計將迎來顯著成長，因為它涵蓋了影響大腦、脊髓和周圍神經的多種疾病。這些疾病包括多發性硬化症、癲癇、帕金森氏症、阿茲海默症以及各種神經病變。此外，治療診斷學利用基因譜分析、分子生物標記和先進的影像技術，實現神經系統疾病的早期精準辨識。因此，精準的診斷設備能夠透過檢測與這些疾病相關的特定生物標記和病理變化，為疾病後續觀察和預後提供支援。

在預測期內，聚合酵素鏈鎖反應(PCR) 領域預計將呈現最高的複合年成長率。

預計在預測期內，聚合酵素鏈鎖反應(PCR) 領域將呈現最高的複合年成長率。這是因為聚合酵素鏈鎖反應(PCR) 至關重要，尤其是在診斷和預後應用方面。治療診斷學利用聚合酵素鏈鎖反應(PCR) 這項分子生物學技術來識別和擴增特定的 DNA 或 RNA 序列。 PCR 是識別感染疾病、基因變異以及與各種疾病相關的生物標記的關鍵工具。基於 PCR 的輔助診斷技術可以預測患者對特定治療的反應。因此，醫療專業人員可以利用 PCR 分析特定的基因變異和生物標記，從而為每位患者選擇最佳治療策略，並最大限度地提高治療效果。

市佔率最大的地區：

隨著北美癌症患者數量的增加，對更有效率、更個人化治療方法的需求日益成長，預計北美將在預測期內佔據最大的市場佔有率。治療診斷學透過提供基於特定生物標記的標靶治療，支持更精準的癌症診斷和治療。此外，個人化醫療方法正日益普及。因此，根據每位患者的基因組成、疾病特徵和生物標記來客製化治療方法的目標是推動市場成長。

複合年成長率最高的地區：

預計在預測期內，歐洲將呈現最高的複合年成長率，這主要得益於癌症和其他慢性疾病發病率的上升，人們對更個性化、更有效率的治療方法的需求日益成長。治療診斷學因其能夠基於特定生物標記提供個人化藥物，從而改善患者預後而備受關注。亞太地區正大力投資加強醫療基礎建設，包括個人化醫療、分子診斷和先進影像技術等領域的項目。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球治療診斷學市場：依疾病類型分類

  • 神經系統疾病
  • 免疫系統疾病
  • 心血管疾病
  • 腫瘤學
    • 結腸癌
    • 乳癌
    • 子宮頸癌
    • 肺癌
  • 其他疾病類型

第6章 全球治療診斷學市場：依技術分類

  • 原位雜合反應
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學
  • 順序
  • 其他技術

第7章 全球治療診斷學市場：依最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 其他最終用戶

第8章 全球治療診斷學市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter, Inc.
  • QIAGEN
  • Abbott Laboratories
  • Myriad Genetics, Inc.
  • Foundation Medicine, Inc.
  • AmeriPath, Inc.
  • Focus Diagnostics
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Leica Biosystems Nussloch GmBH
  • GE Healthcare
  • Pfizer, Inc.
Product Code: SMRC24567

According to Stratistics MRC, the Global Theranostics Market is accounted for $0.9 billion in 2026 and is expected to reach $2.3 billion by 2034 growing at a CAGR of 11.8% during the forecast period. A new area of medicine called "theranostics" blends therapeutic and diagnostic methods into a single, cohesive procedure. Combining the terms "therapy" and "diagnostics," "theranostics" emphasizes how both aspects of patient treatment should be integrated. It seeks to offer accurate and individualized treatment plans based on the unique traits and illness profiles of each patient. Advanced diagnostic methods such as molecular imaging, genetic testing, biomarker analysis, and molecular profiling are used in the field of theranostics.

Market Dynamics:

Driver:

Advancements in diagnostic technologies

The accuracy and sensitivity of illness diagnosis have been improved by sophisticated diagnostic technologies, such as molecular imaging, next-generation sequencing (NGS), and high-resolution imaging modalities including positron emission tomography (PET) and magnetic resonance imaging (MRI). The ability to identify certain biomarkers, genetic variants, or molecular targets linked to illnesses is made possible by this precision, and this is essential in theranostics for the development of tailored medicines. Moreover, early identification in the field of theranostics allows for prompt intervention and customized treatment plans, which may enhance patient outcomes by enabling more powerful and focused therapy.

Restraint:

Lack of properly defined regulations for theranostics tests

The clearance procedure, validation specifications, and quality criteria for theranostic testing might all be unclear in the absence of precise and defined laws. This unpredictability may impede the creation and use of novel diagnostics, delaying the release of ground-breaking theranostic products. Theranostic test market introduction may be delayed by unclear regulatory frameworks and disparate international requirements. Businesses may have trouble navigating complicated regulatory procedures, which might lead to longer wait times for clearances impeding the market growth.

Opportunity:

Increasing research and development initiatives

R&D expenditures support the creation of cutting-edge diagnostic instruments and technology. These developments improve diagnostic test sensitivity, specificity, and accuracy, making it possible to identify disease biomarkers, genetic variants, and molecular targets more accurately. Theranostics relies heavily on improved diagnostics to direct customized treatment plans. The expansion and commercialization of theranostic goods and services are facilitated by successful R&D outcomes on the market giving patients and healthcare professionals access to more individualized and efficient treatment alternatives.

Threat:

Regulatory challenges

New theranostic test and product launches might be delayed by onerous regulatory requirements, convoluted approval procedures, and protracted regulatory approval processes. This hold-up may make it more difficult for patients to receive individualized care and cutting-edge technologies on schedule. Market fragmentation may arise due to variations in approval procedures and regulatory requirements across different locations. Different geographic locations may experience unequal access to theranostic testing due to inconsistent regulatory requirements, which might lead to differences in the availability and uptake of these tests.

Covid-19 Impact

The epidemic brought to light how crucial quick and precise diagnostic testing is. The use of molecular diagnostic methods, such as PCR and assays based on nucleic acid amplification, has increased dramatically in order to identify SARS-CoV-2. The importance of comparable methods in treating other illnesses, such as those addressed by theranostics, has been highlighted by this focus on molecular diagnostics. In order to minimize in-person encounters and maintain continuity of treatment, telemedicine and remote monitoring technologies gained increasing traction. This change may affect how theranostics tactics that include remote monitoring and diagnostics are implemented.

The neurological disorder segment is expected to be the largest during the forecast period

The neurological disorder segment is estimated to have a lucrative growth, owing to a wide range of illnesses involving the brain, spinal cord, and peripheral nerves are referred to as neurological diseases. These illnesses include multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, and different neuropathies. Moreover, theranostics makes use of genetic profiling, molecular biomarkers, and sophisticated imaging methods to facilitate the early and precise identification of neurological illnesses. Thus, accurate diagnostic instruments support illness tracking and prognosis by detecting certain biomarkers or pathological alterations linked to these conditions.

The polymerase chain reaction (PCR) segment is expected to have the highest CAGR during the forecast period

The polymerase chain reaction (PCR) segment is anticipated to witness the highest CAGR growth during the forecast period, as polymerase chain reaction (PCR) is essential, particularly for diagnostic and prognostic uses. Theranostics uses polymerase chain reaction (PCR), a molecular biology technique, to identify and amplify specific DNA or RNA sequences. PCR is a vital tool for finding infections, genetic variants, and biomarkers linked to a variety of disorders. Complementary diagnostic techniques based on PCR can forecast how a patient will react to specific treatments. Hence healthcare professionals may choose the best course of action for each patient by employing PCR to analyze certain genetic variants or biomarkers, which maximizes therapeutic outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the need for more efficient and customized treatment choices that have grown as cancer cases become increasingly common in North America. Theranostics helps with more accurate cancer diagnosis and therapy by providing targeted medicines based on certain biomarkers. Moreover, personalized medicine techniques are becoming more and more popular. Thus, the goal is to customize therapies for each patient according to their genetic composition, illness features, and biomarkers driving the growth of the market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, as growing cancer and other chronic illness incidence has increased need for more individualized and efficient treatment alternatives. Theranostics attracted attention for its promise to enhance patient outcomes because of its capacity to provide tailored medicines based on certain biomarkers. The Asia Pacific area has seen significant investments in enhancing its healthcare infrastructure, encompassing projects in personalized medicine, molecular diagnostics, and sophisticated imaging technology.

Key players in the market

Some of the key players profiled in the Theranostics Market include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., QIAGEN, Abbott Laboratories, Myriad Genetics, Inc., Foundation Medicine, Inc., AmeriPath, Inc., Focus Diagnostics, Illumina, Inc., Agilent Technologies, Inc., Leica Biosystems Nussloch GmBH, GE Healthcare and Pfizer, Inc.

Key Developments:

In November 2023, Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List. The tests complete Roche's panel used for the differential diagnosis of acute viral hepatitis caused by the hepatitis A, B, C and E viruses.

In October 2023, Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics, and the transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

In October 2023, Beckman Coulter Diagnostics, announced it acquired StoCastic, LLC. a leading artificial intelligence company that provides evidence-based decision support for hospital emergency departments (ED).

Disease Types Covered:

  • Neurological Disorder
  • Immunological Disorder
  • Cardiovascular Disease
  • Oncology
  • Other Disease Types

Technologies Covered:

  • In Situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry
  • Sequencing
  • Other Technologies

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Theranostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Neurological Disorder
  • 5.3 Immunological Disorder
  • 5.4 Cardiovascular Disease
  • 5.5 Oncology
    • 5.5.1 Colorectal Cancer
    • 5.5.2 Breast Cancer
    • 5.5.3 Cervical Cancer
    • 5.5.4 Lung Cancer
  • 5.6 Other Disease Types

6 Global Theranostics Market, By Technology

  • 6.1 Introduction
  • 6.2 In Situ Hybridization
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Immunohistochemistry
  • 6.5 Sequencing
  • 6.6 Other Technologies

7 Global Theranostics Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Theranostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.8 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Hoffmann-La Roche Ltd
  • 10.2 Thermo Fisher Scientific Inc.
  • 10.3 Beckman Coulter, Inc.
  • 10.4 QIAGEN
  • 10.5 Abbott Laboratories
  • 10.6 Myriad Genetics, Inc.
  • 10.7 Foundation Medicine, Inc.
  • 10.8 AmeriPath, Inc.
  • 10.9 Focus Diagnostics
  • 10.10 Illumina, Inc.
  • 10.11 Agilent Technologies, Inc.
  • 10.12 Leica Biosystems Nussloch GmBH
  • 10.13 GE Healthcare
  • 10.14 Pfizer, Inc.

List of Tables

  • Table 1 Global Theranostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Theranostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 3 Global Theranostics Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 4 Global Theranostics Market Outlook, By Immunological Disorder (2023-2034) ($MN)
  • Table 5 Global Theranostics Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 6 Global Theranostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 7 Global Theranostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 8 Global Theranostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 9 Global Theranostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 10 Global Theranostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 11 Global Theranostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 12 Global Theranostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 13 Global Theranostics Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 14 Global Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 15 Global Theranostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 16 Global Theranostics Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 17 Global Theranostics Market Outlook, By Other TechnologIEs (2023-2034) ($MN)
  • Table 18 Global Theranostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 19 Global Theranostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 20 Global Theranostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 21 Global Theranostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 22 North America Theranostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 23 North America Theranostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 24 North America Theranostics Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 25 North America Theranostics Market Outlook, By Immunological Disorder (2023-2034) ($MN)
  • Table 26 North America Theranostics Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 27 North America Theranostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 28 North America Theranostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 29 North America Theranostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 30 North America Theranostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 31 North America Theranostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 32 North America Theranostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 33 North America Theranostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 34 North America Theranostics Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 35 North America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 36 North America Theranostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 37 North America Theranostics Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 38 North America Theranostics Market Outlook, By Other TechnologIEs (2023-2034) ($MN)
  • Table 39 North America Theranostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 40 North America Theranostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 41 North America Theranostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 42 North America Theranostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 43 Europe Theranostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 44 Europe Theranostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 45 Europe Theranostics Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 46 Europe Theranostics Market Outlook, By Immunological Disorder (2023-2034) ($MN)
  • Table 47 Europe Theranostics Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 48 Europe Theranostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 49 Europe Theranostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 50 Europe Theranostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 51 Europe Theranostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 52 Europe Theranostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 53 Europe Theranostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 54 Europe Theranostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 55 Europe Theranostics Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 56 Europe Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 57 Europe Theranostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 58 Europe Theranostics Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 59 Europe Theranostics Market Outlook, By Other TechnologIEs (2023-2034) ($MN)
  • Table 60 Europe Theranostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 61 Europe Theranostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 62 Europe Theranostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 63 Europe Theranostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 64 Asia Pacific Theranostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 65 Asia Pacific Theranostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 66 Asia Pacific Theranostics Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 67 Asia Pacific Theranostics Market Outlook, By Immunological Disorder (2023-2034) ($MN)
  • Table 68 Asia Pacific Theranostics Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 69 Asia Pacific Theranostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 70 Asia Pacific Theranostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 71 Asia Pacific Theranostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 72 Asia Pacific Theranostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 73 Asia Pacific Theranostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 74 Asia Pacific Theranostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 75 Asia Pacific Theranostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 76 Asia Pacific Theranostics Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 77 Asia Pacific Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 78 Asia Pacific Theranostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 79 Asia Pacific Theranostics Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 80 Asia Pacific Theranostics Market Outlook, By Other TechnologIEs (2023-2034) ($MN)
  • Table 81 Asia Pacific Theranostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 82 Asia Pacific Theranostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 83 Asia Pacific Theranostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 84 Asia Pacific Theranostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 85 South America Theranostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 86 South America Theranostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 87 South America Theranostics Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 88 South America Theranostics Market Outlook, By Immunological Disorder (2023-2034) ($MN)
  • Table 89 South America Theranostics Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 90 South America Theranostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 91 South America Theranostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 92 South America Theranostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 93 South America Theranostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 94 South America Theranostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 95 South America Theranostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 96 South America Theranostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 97 South America Theranostics Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 98 South America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 99 South America Theranostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 100 South America Theranostics Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 101 South America Theranostics Market Outlook, By Other TechnologIEs (2023-2034) ($MN)
  • Table 102 South America Theranostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 103 South America Theranostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 104 South America Theranostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 105 South America Theranostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 106 Middle East & Africa Theranostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 107 Middle East & Africa Theranostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 108 Middle East & Africa Theranostics Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 109 Middle East & Africa Theranostics Market Outlook, By Immunological Disorder (2023-2034) ($MN)
  • Table 110 Middle East & Africa Theranostics Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 111 Middle East & Africa Theranostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 112 Middle East & Africa Theranostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 113 Middle East & Africa Theranostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 114 Middle East & Africa Theranostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 115 Middle East & Africa Theranostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 116 Middle East & Africa Theranostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 117 Middle East & Africa Theranostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 118 Middle East & Africa Theranostics Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 119 Middle East & Africa Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 120 Middle East & Africa Theranostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 121 Middle East & Africa Theranostics Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 122 Middle East & Africa Theranostics Market Outlook, By Other TechnologIEs (2023-2034) ($MN)
  • Table 123 Middle East & Africa Theranostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 124 Middle East & Africa Theranostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 125 Middle East & Africa Theranostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 126 Middle East & Africa Theranostics Market Outlook, By Other End Users (2023-2034) ($MN)